GlassScriptPhysician profile
Michael D Loughner
NPI 1639216906
$32,345.57
in general payments reported to CMS, 2019-2025
56 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,850 · 2021: $2,005 · 2022: $2,345 · 2023: $2,531 · 2024: $2,947 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,780.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,900.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,986.93 | 2019-2025 | Farxiga, Lokelma |
| Antares Pharma, INC. | $2,300.30 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $1,528.01 | 2019-2025 | Unithroid |
| Amgen INC. | $1,453.25 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $1,365.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,189.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,052.99 | 2019-2025 | |
| Medtronic, INC. | $630.47 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Ibsa Pharma INC. | $472.96 | 2019-2025 | Tirosint, Licart, Tirosint |
| Mannkind Corporation | $424.12 | 2019-2024 | Afrezza |
| Dexcom, INC. | $261.49 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.08 | 2019-2025 | Jardiance |
| Radius Health, INC. | $242.36 | 2019-2025 | Tymlos |
| Amphastar Pharmaceuticals, INC. | $224.29 | 2024-2025 | Baqsimi |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $218.57 | 2019-2020 | |
| Abbott Laboratories | $209.61 | 2021-2025 | Freestyle Libre 3 |
| Cequr Corporation | $187.81 | 2023-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $185.61 | 2021-2025 | Isturisa, Signifor Lar |
| Halozyme INC | $178.09 | 2023 | |
| Merck Sharp & Dohme LLC | $160.95 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $138.20 | 2022-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $131.23 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $121.28 | 2019-2025 | Omnipod |
| Kyowa Kirin, INC. | $121.06 | 2023-2025 | Crysvita |
| Beta Bionics, INC. | $111.34 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $109.85 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $82.51 | 2024-2025 | Yorvipath |
| Valeritas, INC. | $78.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $75.99 | 2019-2020 | |
| Alvogen INC | $75.95 | 2023-2024 | Teriparatide |
| Xeris Pharmaceuticals, INC. | $75.78 | 2021-2025 | Gvoke Hypopen |
| Ipsen Biopharmaceuticals, INC | $68.32 | 2019-2023 | Somatuline Depot |
| Novartis Pharmaceuticals Corporation | $67.38 | 2023-2025 | |
| Grt US Holding, INC. | $61.60 | 2021 | |
| Corcept Therapeutics | $58.29 | 2019-2025 | Korlym |
| Medtronic Minimed, INC. | $58.20 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $53.48 | 2021-2022 | |
| Senseonics, Incorporated | $40.00 | 2019 | |
| Pfizer INC. | $36.02 | 2024-2025 | |
| Amarin Pharma, INC. | $33.27 | 2019 | |
| Acerus Pharmaceuticals Corporation | $33.23 | 2022 | |
| Neurocrine Biosciences, INC. | $33.16 | 2025 | |
| Boston Scientific Corporation | $29.65 | 2024 | Wavewriter Alpha Prime 16 |
| Lifescan, INC. | $26.42 | 2022 | |
| Sequel Med Tech, LLC | $24.89 | 2025 | Twiist |
| Horizon Therapeutics Plc | $24.01 | 2020 | |
| Clarus Therapeutics INC. | $22.11 | 2021 | |
| Becton, Dickinson and Company | $20.98 | 2019 | |
| Eusa Pharma (US) LLC | $20.49 | 2022 | |
| Esperion Therapeutics, INC. | $17.91 | 2025 | Nexletol |
| Ascensia Diabetes Care US INC. | $17.14 | 2024 | |
| Companion Medical, INC. | $13.47 | 2019 | |
| Aytu Biopharma, INC. | $12.66 | 2019 | |
| Zealand Pharma US, INC. | $11.16 | 2021 | |
| Amryt Pharma Holdings LTD | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Loughner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.